CLAIMS

1. An antigenic construct comprising an antigenic peptide corresponding to a sequence within the tau protein comprising a phospho-epitope, which peptide is (a) modified through linkage to a lipophilic or hydrophobic moiety that facilitates insertion into the lipid bilayer of a liposome and (b) reconstituted in a liposome such that the peptide is presented on the surface of the liposome.

2. The antigenic construct of claim 1, wherein said peptide consists of between 5 and 25 amino acid residues.

3. The antigenic construct of any one of the preceding claims, wherein said peptide comprises a major pathological phospho-epitope of protein tau corresponding to a sequence within the tau protein featuring a characteristic phosphorylation pattern which is associated with a pathologic condition or disorder.

4. The antigenic construct of any one of the preceding claims, wherein said peptide does not contain a T-cell epitope.

5. The antigenic construct of any one of the preceding claims, wherein said peptide is presented in a highly repetitive array on the surface of the liposome.

6. The antigenic construct of any one of the preceding claims, wherein said peptide upon administration to an animal or a human in form of a pharmaceutical composition, is capable of eliciting a conformation specific and T-cell independent immune response.

7. The antigenic construct according to any one of the preceding claims, wherein the lipophilic or hydrophobic moiety is a fatty acid, a triglyceride, a diglyceride, a steroid, a sphingolipid, a glycolipid or a phospholipid.

8. The antigenic construct according to any one of the preceding claims, wherein the lipophilic or hydrophobic moiety is a fatty acid, particularly a fatty acid with a carbon back bone of at least 10, particularly at least 12 carbon atoms, particularly at least 16 carbon atoms.

9. The antigenic construct according to any one of the preceding claims, wherein the hydrophobic moiety is palmitic acid.

10. The antigenic construct according to any one of the preceding claims, wherein said hydrophilic or hydrophobic moiety is covalently bound to each of the termini of the peptide or peptide fragment through at least one, particularly one or two amino acids such as, for example, lysine, glutamic acid and cysteine.

11. The antigenic construct according to any one of the preceding claims, wherein said peptide is further modified through linkage to a hydrophilic moiety.

12. The antigenic construct according to claim 11, wherein said hydrophilic moiety is polyethylene glycol.

13. The antigenic construct according to any one of the preceding claims, wherein said tau protein is a human protein.

14. The antigenic construct according to claim 13, wherein said antigenic peptide has an amino acid sequence of:

a. SEQ ID NO: 2 or an amino acid sequence of SEQ ID NO: 2 modified through conservative substitution, deletion or insertion of at least one but not more than 5 amino acids and still has the same antigenic potential as the unmodified sequence;

b. SEQ ID NO: 3 or an amino acid sequence of SEQ ID NO: 3 modified through conservative substitution, deletion or insertion of at least one but not more than 5 amino acids and still has the same antigenic potential as the unmodified sequence;

c. SEQ ID NO: 4 or an amino acid sequence of SEQ ID NO: 4 modified through conservative substitution, deletion or insertion of at least one but not more than 5 amino acids and still has the same antigenic potential as the unmodified sequence;

d. SEQ ID NO: 5 or an amino acid sequence of SEQ ID NO: 5 modified through conservative substitution, deletion or insertion of at least one but not more than 5 amino acids and still has the same antigenic potential as the unmodified sequence;

e. SEQ ID NO: 6 or an amino acid sequence of SEQ ID NO: 6 modified through conservative substitution, deletion or insertion of at least one but not more than 5 amino acids and still has the same antigenic potential as the unmodified sequence;

f. SEQ ID NO: 7 or an amino acid sequence of SEQ ID NO: 7 modified through conservative substitution, deletion or insertion of at least one but not more than 5 amino acids and still has the same antigenic potential as the unmodified sequence;

g. SEQ ID NO: 8 or an amino acid sequence of SEQ ID NO: 8 modified through conservative substitution, deletion or insertion of at least one but not more than 5 amino acids and still has the same antigenic potential as the unmodified sequence; or

h. SEQ ID NO: 9 or an amino acid sequence of SEQ ID NO: 9 modified through conservative substitution, deletion or insertion of at least one but not more than 5 amino acids and still has the same antigenic potential as the unmodified sequence.

15. The antigenic construct according to claim 14, wherein the antigenic peptide corresponds to a human tau protein between

a. position 5-20 and wherein the tyrosine at position 18 is phosphorylated;
b. position 196-221 and wherein at least one, particularly at least two, particularly at least 3, but especially all 4 of the amino acids at positions 202, 205, 212, 214 are phosphorylated;
c. position 393-408 and wherein at least one of the amino acids, but especially all amino acids at positions 396, 404 are phosphorylated;
d. position 401- 418 and wherein at least one of the amino acids, but especially all amino acids at positions 404 and 409 are phosphorylated;

e. position 200-216 and wherein at least one of the amino acids, but especially all amino acids at positions 202, 205, 212 and 214, are phosphorylated;
f. position 407-418 and wherein the serine at position 409 is phosphorylated; or
g. position 399-408 and wherein the serine at position 404 is phosphorylated.

16. The antigenic construct according to claim 14, wherein said antigenic peptide has an amino acid sequence identity to:

a. SEQ ID NO: 2 of at least 95%, and the immunogenic activity of said antigenic peptide of SEQ ID NO: 2, wherein the amino acid residue corresponding to amino acid residue 18 (P-Tyr_{18}) of SEQ ID NO: 2 is phosphorylated;

b. SEQ ID NO: 3 of at least 95%, and the immunogenic activity of said antigenic peptide of SEQ ID NO: 3, wherein at least one, particularly at least 2 of amino acid residues corresponding to amino acid residues 212 (P-Thr_{212}) and 214 (P-Ser_{214}) of SEQ ID NO: 3 are phosphorylated;

c. SEQ ID NO: 4 of at least 95%, and the immunogenic activity of said antigenic peptide of SEQ ID NO: 4, wherein at least one, particularly at least 2 of amino acid residues corresponding to amino acid residues 202 (P-Ser_{202}) and 205 (P-Thr_{205}) of SEQ ID NO: 4 are phosphorylated;

d. SEQ ID NO: 5 of at least 95%, and the immunogenic activity of said antigenic peptide of SEQ ID NO: 5, wherein at least one, but especially all of amino acid residues corresponding to amino acid residues 396 (P-Ser_{396}) and 404 (P-Ser_{404}) of SEQ ID NO: 5 are phosphorylated;

e. SEQ ID NO: 6 of at least 95%, and the immunogenic activity of said antigenic peptide of SEQ ID NO: 6, wherein at least one, but especially all of amino acid residues corresponding to amino acid residues 404 (P-Ser_{404}) and 409 (P-Ser_{409}) of SEQ ID NO: 6 are phosphorylated;

f. SEQ ID NO: 7 of at least 95%, and the immunogenic activity of said antigenic peptide of SEQ ID NO: 7, wherein at least one, particularly at

least 2, particularly a least 3, but especially all of amino acid residues corresponding to amino acid residues 202 (P-Ser_{202}), 205 (P-Thr_{205}), 212 (P-Thr_{212}), and 214 (P-Ser_{214}) of SEQ ID NO: 7 are phosphorylated;

g. SEQ ID NO: 8 of at least 95%, and the immunogenic activity of said antigenic peptide of SEQ ID NO: 8, wherein the amino acid residue corresponding to amino acid residue 409 (P-Ser_{409}) of SEQ ID NO: 8 is phosphorylated; or

h. SEQ ID NO: 9 of at least 95%, and the immunogenic activity of said antigenic peptide of SEQ ID NO: 9, wherein the amino acid residue corresponding to amino acid residue 404 (P-Ser_{404}) of SEQ ID NO: 9 is phosphorylated.

17. The antigenic construct according to claim 14, wherein said tau peptide has an amino acid sequence of SEQ ID NO: 2; SEQ ID NO: 3; SEQ ID NO: 4; SEQ ID NO: 5; SEQ ID NO: 6; SEQ ID NO: 7; SEQ ID NO: 8; or SEQ ID NO: 9.

18. The antigenic construct according to any one of the preceding claims, or a combination thereof, for use in the treatment of neurodegenerative disorders such as tauopathies.

19. The antigenic construct according to claim 18 for use in the treatment of Alzheimer's Disease.

20. A pharmaceutical composition comprising the antigenic construct of any one of the preceding claims or a combination thereof.

21. A pharmaceutical composition according to claim 20, which contains a pharmaceutically acceptable adjuvant and/or immunomodulator.

22. A pharmaceutical composition which is a vaccine comprising an antigenic peptide of SEQ ID NO: 5, which peptide is modified by palmitic acid covalently bound to each of the termini of the peptide, and further comprising a pharmaceutically acceptable adjuvant and/or immunomodulator.

23. A pharmaceutical composition which is a vaccine comprising an antigenic peptide of SEQ ID NO: 3, which peptide is modified by palmitic acid covalently bound to each of the termini of the peptide, and further comprising a pharmaceutically acceptable adjuvant and/or immunomodulator.

24. A pharmaceutical composition which is a vaccine comprising an antigenic peptide of SEQ ID NO: 3 and SEQ ID NO: 4, which peptides are modified by palmitic acid covalently bound to each of the termini of the peptides, and further comprising a pharmaceutically acceptable adjuvant and/or immunomodulator.

25. The pharmaceutical composition of any one of claims 22 to 24, wherein said antigenic peptide of SEQ ID NO: 5, SEQ ID NO: 3 and SEQ ID NO: 4, respectively, is a tetrapalmitoylated peptide, wherein two palmitic acid moieties are bound to each of the termini of the peptide.

26. A pharmaceutical composition according to any one of claims 21 to 25, wherein the immunomodulator is detoxified lipid A, such as monophosphoryl or diphosphoryl lipid A.

27. A pharmaceutical composition according to any one of claims 20 to 26 for use in the treatment of a neurodegenerative disorder such as tauopathy.

28. A pharmaceutical composition according to claim 27 for the treatment of diseases and disorders which are caused by or associated with the formation of neurofibrillary lesions, the predominant brain pathology in tauopathy comprising a heterogenous group of neurodegenerative diseases or disorders including diseases or disorders which show co-existence of tau and amyloid pathologies including, but not limited to, Alzheimer's Disease, Creutzfeldt-Jacob disease, Dementia pugilistica, Down's Syndrome, Gerstmann-Sträussler-Scheinker disease, inclusion-body myositis, and prion protein cerebral amyloid angiopathy, traumatic brain injury and further diseases or disorders which do not show a distinct amyloid pathology including, but not limited to, amyotrophic lateral sclerosis/parkinsonism-dementia complex of Guam, Non-Guamanian motor

neuron disease with neurofibrillary tangles, argyrophilic grain dementia, corticobasal degeneration, diffuse neurofibrillary tangles with calcification, frontotemporal dementia with parkinsonism linked to chromosome 17, Hallevorden-Spatz disease, multiple system atrophy, Niemann-Pick disease, type C, Pick's disease, progressive subcortical gliosis, progressive supranuclear palsy, Subacute sclerosing panencephalitis, Tangle only dementia, Postencephalitic Parkinsonism and Myotonic dystrophy.

29. A pharmaceutical composition according to claim 28 for use in the treatment of Alzheimer's Disease.

30. Use of a therapeutic pharmaceutical composition according to any one of claims 20 to 26 in the manufacture of a medicament for the treatment of a neurodegenerative disease or disorder such as tauopathy in an animal, particularly in a mammal, but especially in a human.

31. Use according to claim 30 for the treatment of diseases and disorders which are caused by or associated with the formation of neurofibrillary lesions, the predominant brain pathology in tauopathy comprising a heterogenous group of neurodegenerative diseases or disorders including diseases or disorders which show co-existence of tau and amyloid pathologies including, but not limited to, Alzheimer's Disease, Creutzfeldt-Jacob disease, Dementia pugilistica, Down's Syndrome, Gerstmann-Straussier-Scheinker disease, inclusion-body myositis, and prion protein cerebral amyloid angiopathy, traumatic brain injury and further diseases or disorders which do not show a distinct amyloid pathology including, but not limited to, amyotrophic lateral sclerosis/parkinsonism-dementia complex of Guam, Non-Guamanian motor neuron disease with neurofibrillary tangles, argyrophilic grain dementia, corticobasal degeneration, diffuse neurofibrillary tangles with calcification, frontotemporal dementia with parkinsonism linked to chromosome 17, Hallevorden-Spatz disease, multiple system atrophy, Niemann-Pick disease, type C, Pick's disease, progressive subcortical gliosis, progressive supranuclear palsy, Subacute sclerosing panencephalitis Tangle only dementia, Postencephalitic Parkinsonism and Myotonic dystrophy.

32. Use of an antigenic peptide or a therapeutic composition as claimed in any of the preceding claims in the manufacture of a medicament for inducing an immune response in an animal, particularly a mammal or a human, suffering from a neurodegenerative disorder such as tauopathy.

33. A peptide fragment representing an epitope, the sequence of which is comprised in a peptide sequence selected from the group of sequences as given in SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8 and SEQ ID NO: 9.

CLAIMS

1. An antigenic construct comprising an antigenic peptide corresponding to a sequence within the tau protein comprising a phospho-epitope, which peptide is (a) modified through linkage to a lipophilic or hydrophobic moiety that facilitates insertion into the lipid bilayer of a liposome and (b) reconstituted in a liposome such that the peptide is presented on the surface of the liposome.

2. The antigenic construct of claim 1, wherein said peptide consists of between 5 and 25 amino acid residues.

3. The antigenic construct of any one of the preceding claims, wherein said peptide comprises a major pathological phospho-epitope of protein tau corresponding to a sequence within the tau protein featuring a characteristic phosphorylation pattern which is associated with a pathologic condition or disorder.

4. The antigenic construct of any one of the preceding claims, wherein said peptide does not contain a T-cell epitope.

5. The antigenic construct of any one of the preceding claims, wherein said peptide is presented in a highly repetitive array on the surface of the liposome.

6. The antigenic construct of any one of the preceding claims, wherein said peptide upon administration to an animal or a human in form of a pharmaceutical composition, is capable of eliciting a conformation specific and T-cell independent immune response.

7. The antigenic construct according to any one of the preceding claims, wherein the lipophilic or hydrophobic moiety is a fatty acid, a triglyceride, a diglyceride, a steroid, a sphingolipid, a glycolipid or a phospholipid.

8. The antigenic construct according to any one of the preceding claims, wherein the lipophilic or hydrophobic moiety is a fatty acid, particularly a fatty acid with a carbon back bone of at least 10, particularly at least 12 carbon atoms, particularly at least 16 carbon atoms.

9. The antigenic construct according to any one of the preceding claims, wherein the hydrophobic moiety is palmitic acid.

10. The antigenic construct according to any one of the preceding claims, wherein said hydrophilic or hydrophobic moiety is covalently bound to each of the termini of the peptide or peptide fragment through at least one, particularly one or two amino acids such as, for example, lysine, glutamic acid and cystein.

11. The antigenic construct according to any one of the preceding claims, wherein said peptide is further modified through linkage to a hydrophilic moiety.

12. The antigenic construct according to claim 11, wherein said hydrophilic moiety is polyethylene glycol.

13. The antigenic construct according to any one of the preceding claims, wherein said tau protein is a human protein.

14. The antigenic construct according to claim 13, wherein said antigenic peptide has an amino acid sequence of:

a. SEQ ID NO: 2 or an amino acid sequence of SEQ ID NO: 2 modified through conservative substitution, deletion or insertion of at least one but not more than 5 amino acids and still has the same antigenic potential as the unmodified sequence;

b. SEQ ID NO: 3 or an amino acid sequence of SEQ ID NO: 3 modified through conservative substitution, deletion or insertion of at least one but not more than 5 amino acids and still has the same antigenic potential as the unmodified sequence;

c. SEQ ID NO: 4 or an amino acid sequence of SEQ ID NO: 4 modified through conservative substitution, deletion or insertion of at least one but not more than 5 amino acids and still has the same or essentially the same antigenic potential as the unmodified sequence;

d. SEQ ID NO: 5 or an amino acid sequence of SEQ ID NO: 5 modified through conservative substitution, deletion or insertion of at least one

but not more than 5 amino acids and still has the same antigenic potential as the unmodified sequence;

e. SEQ ID NO: 6 or an amino acid sequence of SEQ ID NO: 6 modified through conservative substitution, deletion or insertion of at least one but not more than 5 amino acids and still has the same antigenic potential as the unmodified sequence;

f. SEQ ID NO: 7 or an amino acid sequence of SEQ ID NO: 7 modified through conservative substitution, deletion or insertion of at least one but not more than 5 amino acids and still has the same antigenic potential as the unmodified sequence;

g. SEQ ID NO: 8 or an amino acid sequence of SEQ ID NO: 8 modified through conservative substitution, deletion or insertion of at least one but not more than 5 amino acids and still has the same antigenic potential as the unmodified sequence; or

h. SEQ ID NO: 9 or an amino acid sequence of SEQ ID NO: 9 modified through conservative substitution, deletion or insertion of at least one but not more than 5 amino acids and still has the same antigenic potential as the unmodified sequence.

15. The antigenic construct according to claim 14, wherein the antigenic peptide corresponds to a human tau protein between

a. position 5-20 and wherein the tyrosine at position 18 is phosphorylated;
b. position 196-221 and wherein at least one, particularly at least two, particularly at least 3, but especially all 4 of the amino acids at positions 202, 205, 212, 214 are phosphorylated;
c. position 393-408 and wherein at least one of the amino acids, but especially all amino acids at positions 396, 404 are phosphorylated;
d. position 401- 418 and wherein at least one of the amino acids, but especially all amino acids at positions 404 and 409 are phosphorylated;
e. position 200-216 and wherein at least one of the amino acids, but especially all amino acids at positions 202, 205, 212 and 214, are phosphorylated;

f. position 407-418 and wherein the serine at position 409 is phosphorylated; or

g. position 399-408 and wherein the serine at position 404 is phosphorylated.

16. The antigenic construct according to claim 14, wherein said antigenic peptide has an amino acid sequence identity to:

a. SEQ ID NO: 2 of at least 95%, and the immunogenic activity of said antigenic peptide of SEQ ID NO: 2, wherein the amino acid residue corresponding to amino acid residue 18 (P-Tyr_{18}) of SEQ ID NO: 2 is phosphorylated;

b. SEQ ID NO: 3 of at least 95%, and the immunogenic activity of said antigenic peptide of SEQ ID NO: 3, wherein at least one, particularly at least 2 of amino acid residues corresponding to amino acid residues 212 (P-Thr_{212}) and 214 (P-Ser_{214}) of SEQ ID NO: 3 are phosphorylated;

c. SEQ ID NO: 4 of at least 95%, and the immunogenic activity of said antigenic peptide of SEQ ID NO: 4, wherein at least one, particularly at least 2 of amino acid residues corresponding to amino acid residues 202 (P-Ser_{202}) and 205 (P-Thr_{205}) of SEQ ID NO: 4 are phosphorylated;

d. SEQ ID NO: 5 of at least 95%, and the immunogenic activity of said antigenic peptide of SEQ ID NO: 5, wherein at least one, but especially all of amino acid residues corresponding to amino acid residues 396 (P-Ser_{396}) and 404 (P-Ser_{404}) of SEQ ID NO: 5 are phosphorylated;

e. SEQ ID NO: 6 of at least 95%, and the immunogenic activity of said antigenic peptide of SEQ ID NO: 6, wherein at least one, but especially all of amino acid residues corresponding to amino acid residues 404 (P-Ser_{404}) and 409 (P-Ser_{409}) of SEQ ID NO: 6 are phosphorylated;

f. SEQ ID NO: 7 of at least 95%, and the immunogenic activity of said antigenic peptide of SEQ ID NO: 7, wherein at least one, particularly at least 2, particularly a least 3, but especially all of amino acid residues corresponding to amino acid residues 202 (P-Ser_{202}), 205 (P-Thr_{205}), 212 (P-Thr_{212}), and 214 (P-Ser_{214}) of SEQ ID NO: 7 are phosphorylated;

g. SEQ ID NO: 8 of at least 95%, and the immunogenic activity of said antigenic peptide of SEQ ID NO: 8, wherein the amino acid residue corresponding to amino acid residue 409 (P-Ser_{409}) of SEQ ID NO: 8 is phosphorylated; or

h. SEQ ID NO: 9 of at least 95%, and the immunogenic activity of said antigenic peptide of SEQ ID NO: 9, wherein the amino acid residue corresponding to amino acid residue 404 (P-Ser_{404}) of SEQ ID NO: 9 is phosphorylated.

17. The antigenic construct according to claim 14, wherein said tau peptide has an amino acid sequence of SEQ ID NO: 2; SEQ ID NO: 3; SEQ ID NO: 4; SEQ ID NO: 5; SEQ ID NO: 6; SEQ ID NO: 7; SEQ ID NO: 8; or SEQ ID NO: 9.

18. The antigenic construct according to any one of the preceding claims, or a combination thereof, for use in the treatment of neurodegenerative disorders such as tauopathies.

19. The antigenic construct according to claim 18 for use in the treatment of Alzheimer's Disease.

20. A pharmaceutical composition comprising the antigenic construct of any one of the preceding claims or a combination thereof.

21. A pharmaceutical composition according to claim 20, which contains a pharmaceutically acceptable carrier and/or a pharmaceutically acceptable adjuvant and/or an immunomodulator and/or a diluent and/or an excipient.

22. A pharmaceutical composition comprising an antigenic peptide of SEQ ID NO: 5, which peptide is modified by palmitic acid covalently bound to each of the termini of the peptide, and further comprising a pharmaceutically acceptable carrier and/or a pharmaceutically acceptable adjuvant and/or an immunomodulator and/or a diluent and/or an excipient.

23. A pharmaceutical composition comprising an antigenic peptide of SEQ ID NO: 3, which peptide is modified by palmitic acid covalently bound to each of the termini of the peptide, and further comprising a pharmaceutically

acceptable carrier and/or a pharmaceutically acceptable adjuvant and/or an immunomodulator and/or a diluent and/or an excipient.

24. A pharmaceutical composition comprising an antigenic peptide of SEQ ID NO: 3 and SEQ ID NO: 4, which peptides are modified by palmitic acid covalently bound to each of the termini of the peptides, and further comprising a pharmaceutically acceptable carrier and/or a pharmaceutically acceptable adjuvant and/or an immunomodulator and/or a diluent and/or an excipient.

25. The pharmaceutical composition of any one of claims 22 to 24, wherein said antigenic peptide of SEQ ID NO: 5, SEQ ID NO: 3 and SEQ ID NO: 4, respectively, is a tetrapalmitoylated peptide, wherein two palmitic acid moieties are bound to each of the termini of the peptide.

26. A pharmaceutical composition according to any one of claims 21 to 25, which is a vaccine comprising detoxified lipid A, such as monophosphoryl or diphosphoryl lipid A, as an immunomodulator.

27. The pharmaceutical composition of claim 26 comprising the peptide of SEQ ID NO: 5, which is tetrapalmitoylated and monophosphoryl Lipid A.

28. The pharmaceutical composition of claim 27, wherein two molecules of palmitic acid are covalently attached to the N-terminal end and two molecules of palmitic acid are covalently attached to the C-terminal end of the antigenic peptide.

29. A pharmaceutical composition according to any one of claims 20 to 28 for use in the treatment of a neurodegenerative disorder such as tauopathy.

30. A pharmaceutical composition according to claim 29 for the treatment of diseases and disorders which are caused by or associated with the formation of neurofibrillary lesions, the predominant brain pathology in tauopathy comprising a heterogenous group of neurodegenerative diseases or disorders including diseases or disorders which show co-existence of tau and amyloid pathologies including, but not limited to, Alzheimer's Disease, Creutzfeldt-Jacob disease, Dementia pugilistica, Down's Syndrome, Gerstmann-Sträussler-Scheinker disease, inclusion-

body myositis, and prion protein cerebral amyloid angiopathy, traumatic brain injury and further diseases or disorders which do not show a distinct amyloid pathology including, but not limited to, amyotrophic lateral sclerosis/parkinsonism-dementia complex of Guam, Non-Guamanian motor neuron disease with neurofibrillary tangles, argyrophilic grain dementia, corticobasal degeneration, diffuse neurofibrillary tangles with calcification, frontotemporal dementia with parkinsonism linked to chromosome 17, Hallevorden-Spatz disease, multiple system atrophy, Niemann-Pick disease, type C, Pick's disease, progressive subcortical gliosis, progressive supranuclear palsy, Subacute sclerosing panencephalitis, Tangle only dementia, Postencephalitic Parkinsonism and Myotonic dystrophy.

31. A pharmaceutical composition according to claim 30 for use in the treatment of Alzheimer's Disease.

32. Use of a therapeutic pharmaceutical composition according to any one of claims 20 to 28 in the manufacture of a medicament for the treatment of a neurodegenerative disease or disorder such as tauopathy in an animal, particularly in a mammal, but especially in a human.

33. Use according to claim 32 for the treatment of diseases and disorders which are caused by or associated with the formation of neurofibrillary lesions, the predominant brain pathology in tauopathy comprising a heterogenous group of neurodegenerative diseases or disorders including diseases or disorders which show co-existence of tau and amyloid pathologies including, but not limited to, Alzheimer's Disease, Creutzfeldt-Jacob disease, Dementia pugilistica, Down's Syndrome, Gerstmann-Straussier-Scheinker disease, inclusion-body myositis, and prion protein cerebral amyloid angiopathy, traumatic brain injury and further diseases or disorders which do not show a distinct amyloid pathology including, but not limited to, amyotrophic lateral sclerosis/parkinsonism-dementia complex of Guam, Non-Guamanian motor neuron disease with neurofibrillary tangles, argyrophilic grain dementia, corticobasal degeneration, diffuse neurofibrillary tangles with calcification, frontotemporal dementia with parkinsonism linked to chromosome 17, Hallevorden-Spatz disease, multiple system atrophy, Niemann-Pick disease, type C, Pick's disease,

progressive subcortical gliosis, progressive supranuclear palsy, Subacute sclerosing panencephalitis Tangle only dementia, Postencephalitic Parkinsonism and Myotonic dystrophy.

34. Use of an antigenic peptide or a therapeutic composition as claimed in any of the preceding claims in the manufacture of a medicament for inducing an immune response in an animal, particularly a mammal or a human, suffering from a neurodegenerative disorder such as tauopathy.